Work

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.1042

Authors: M. Beeram, I. Krop, S. Modi, A. Tolcher, N. Rabbee, S. Girish, J. Tibbitts, S. Holden, S. Lutzker, H. Burris

Institutions: Memorial Sloan Kettering Cancer Center, Genentech, Sarah Cannon, Dana-Farber Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1955007080

Cites:

Cited by: 39

Related to: 10